Ironwood Pharmaceuticals (IRWD) Cash & Equivalents (2010 - 2026)

Ironwood Pharmaceuticals (IRWD) has 17 years of Cash & Equivalents data on file, last reported at $220.5 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents rose 103.23% year-over-year to $220.5 million; the trailing twelve-month figure through Mar 2026 stood at $220.5 million (up 103.23% YoY), and the FY2025 full-year result was $215.5 million, up 143.29% from the prior year.
• Cash & Equivalents rose to $220.5 million in Q1 2026, from $215.5 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $740.3 million in Q1 2023 to a low of $88.2 million in Q3 2024.
• A 5-year average of $272.2 million and a median of $140.4 million in 2025 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents slumped 85.96% in 2023 and jumped 143.29% in 2025, its largest moves.
• Tracing IRWD's Cash & Equivalents over 5 years: stood at $656.2 million in 2022, then tumbled by 85.96% to $92.2 million in 2023, then fell by 3.9% to $88.6 million in 2024, then jumped by 143.29% to $215.5 million in 2025, then rose by 2.33% to $220.5 million in 2026.
• Business Quant data shows IRWD's Cash & Equivalents at $220.5 million in Q1 2026, $215.5 million in Q4 2025, and $140.4 million in Q3 2025.